Finance Watch: Theravance Eliminates Debt In $1.1bn Trelegy Royalty Sell-Off

Also, Ultragenyx Leverages Crysvita Royalties In $500m Deal

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.